Advancing High-Quality Value Assessments of Health Care Interventions

Value in Health

Volumn 20, Issue 2, 2017, Pages 181-184

  Doshi, Jalpa A ^a   Willke, Richard J ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b International Society for Pharmacoeconomics and Outcomes Research (ISPOR)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG;

CONSULTATION; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DOCTOR PATIENT RELATION; ECONOMIC EVALUATION; EDITORIAL; FACE VALIDITY; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; INVESTMENT; MEDICAL SOCIETY; PATIENT PREFERENCE; PEER REVIEW; PILOT STUDY; PRIORITY JOURNAL; PUBLICATION; RESOURCE ALLOCATION; SHARED DECISION MAKING; COST BENEFIT ANALYSIS; ECONOMICS; STANDARDS;

COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; HUMANS; QUALITY OF HEALTH CARE;

EID: 85010996017     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2016.12.012     Document Type: Editorial

References (34)

1. [1] Anderson, J.L., Heidenreich, P.A., Barnett, P.G., et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on performance measures and task force on practice guidelines. J Am Coll Cardiol 63 (2014), 2304–2322.
2. [2] Schnipper, L.E., Davidson, N.E., Wollins, D.S., et al. American Society of Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol 33 (2015), 2563–2577.
3. [3] Schnipper, L.E., Davidson, H.E., Wollins, D.S., et al. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J Clin Oncol 34 (2016), 2925–2934.
4. [4] Institute for Clinical and Economic Review. Value assessment project, a framework to guide payer assessment of the value of medical services. 2015. Available from: http://www.icer-review.org/impact-and-outcomes/value-assessment-project/. [Accessed December 4, 2016].
5. [5] Memorial Sloan Kettering Cancer Center. DrugAbacus FAQs. Available from: www.drugabacus.org/faqs. [Accessed December 4, 2016].
6. [6] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) with NCCN Evidence Blocks™. Available from: www.nccn.org/evidenceblocks/. [Accessed December 4, 2016].
7. [7] FasterCures. Patient perspective value framework draft methodology. Available from: www.fastercures.org/reports/view/61. [Accessed December 8, 2016].
8. [8] International Society for Pharmacoeconomics and Outcomes Research. Initiative on US Value Assessment Frameworks. Available from: www.ispor.org/ValueAssessmentFrameworks. [Accessed December 8, 2016].
9. [9] Mandelblatt, J.S., Ramsey, S.D., Lieu, T.A., Phelps, C.E., Evaluating frameworks that provide value measures for health care interventions. Value Health 20 (2017), 185–192.
10. [10] Cohen, J.T., Anderson, J.E., Neumann, P.J., Three sets of case studies suggest logic and consistency challenges with value frameworks. Value Health 20 (2017), 193–199.
11. [11] Bentley, T.G.K., Cohen, J.T., Elkin, E.B., et al. Validity and reliability of value assessment frameworks for new cancer drugs. Value Health 20 (2017), 200–205.
12. [12] Cookson, R., Mirelman, A.J., Griffin, S., et al. Using cost-effectiveness analysis to address health equity concerns. Value Health 20 (2017), 206–212.
13. [13] Garrison, L.P. Jr, Kamal-Bahl, S., Towse, A., Toward a broader concept of value: identifying and defining elements for an expanded cost-effectiveness analysis. Value Health 20 (2017), 213–216.
14. [14] Shafrin, J., Schwartz, T.T., Okoro, T., Romley, J.A., Patient versus physician valuation of durable survival gains: implications for value framework assessments. Value Health 20 (2017), 217–223.
15. [15] Taylor, M.J., Chilton, S., Ronaldson, S., Metcalf, H., Nielsen, J.S., Comparing increments in utility of health: an individual-based approach. Value Health 20 (2017), 224–229.
16. [16] Ciarametaro, M., Abedi, S., Sohn, A., Ge, C.F., Odedara, N., Dubois, R., Concerns around budget impact thresholds: not all drugs are the same. Value Health 20 (2017), 230–233.
17. [17] Sculpher, M.J., Claxton, K., Pearson, S.D., Developing a value framework: the need to reflect the opportunity costs of funding decisions. Value Health 20 (2017), 234–239.
18. [18] Camejo, R.R., Miraldo, M., Rutten, F., Cost-effectiveness and dynamic efficiency: does the solution lie within?. Value Health 20 (2017), 240–243.
19. [19] Garber, A.M., Phelps, C.E., Economic foundations of cost-effectiveness analysis. J Health Econ 16 (1997), 1–31.
20. [20] Meltzer, D.O., Basu, A., Sculpher, M.J., Theoretical foundations of cost-effectiveness analysis in health and medicine. Neumann, P.J., Sanders, G.D., Russell, L.B., et al. (eds.) Cost-Effectiveness in Health and Medicine, 2016, Oxford University Press, New York, NY, 39–66.
21. ®—10 years of developing an international framework to share multi-dimensional value assessment. Value Health 20 (2017), 244–250.
22. [22] Phelps, C.E., Madhavan, G., Using multicriteria approaches to assess the value of health care. Value Health 20 (2017), 251–255.
23. [23] Thokala, P., Devlin, N., Marsh, K., et al. Multiple criteria decision analysis for health care decision making—an introduction: report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health 19 (2016), 1–13.
24. [24] Marsh, K., IJzerman, M., Thokala, P., et al. Multiple criteria decision analysis for health care decision making—emerging good practices: report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health 19 (2016), 125–137.
25. [25] Baltussen, R., Jansen, M.P.M., Bijlmakers, L., et al. Value assessment frameworks for HTA agencies: the organization of evidence-informed deliberative processes. Value Health 20 (2017), 256–260.
26. [26] Basu, A., Sullivan, S.D., Towards a hedonic value framework in health care. Value Health 20 (2017), 261–265.
27. [27] Mühlbacher, A.C., Sadler, A., The probabilistic efficiency frontier: a framework for cost-effectiveness analysis in Germany put into practice for hepatitis C treatment options. Value Health 20 (2017), 266–272.
28. [28] Connolly, M.P., Kotsopoulos, N., Postma, M.J., Bhatt, A., The fiscal consequences attributed to changes in morbidity and mortality linked to investments in health care: a government perspective analytic framework. Value Health 20 (2017), 273–277.
29. [29] Pauly, M.V., The questionable economic case for value-based drug pricing in market health systems. Value Health 20 (2017), 278–282.
30. [30] Allen, J.D., Stewart, M.D., Roberts, S.A., Sigal, E.V., The value of addressing patient preferences. Value Health 20 (2017), 283–285.
31. [31] Perfetto, E.M., Oehrlein, E.M., Boutin, M., Reid, S., Gascho, E., Value to whom? The patient voice in the value discussion. Value Health 20 (2017), 286–291.
32. [32] Armstrong, M.J., Mullins, C.D., Value assessment at the point of care: incorporating patient values throughout care delivery and a draft taxonomy of patient values. Value Health 20 (2017), 292–295.
33. [33] Miller, K.L., Woodcock, J., Value assessment in the regulatory context. Value Health 20 (2017), 296–298.
34. [34] Sorenson, C., Lavezzari, G., Daniel, G., et al. Advancing value assessment in the United States: a multistakeholder perspective. Value Health 20 (2017), 299–307.